Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

In Search of Biomarkers for Autism Spectrum Disorder.

Del Valle Rubido M, McCracken JT, Hollander E, Shic F, Noeldeke J, Boak L, Khwaja O, Sadikhov S, Fontoura P, Umbricht D.

Autism Res. 2018 Nov;11(11):1567-1579. doi: 10.1002/aur.2026. Epub 2018 Oct 15.

2.

Cerebral blood flow predicts differential neurotransmitter activity.

Dukart J, Holiga Š, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro F.

Sci Rep. 2018 Mar 6;8(1):4074. doi: 10.1038/s41598-018-22444-0.

3.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1924. doi: 10.1038/npp.2017.92.

4.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1914-1923. doi: 10.1038/npp.2016.232. Epub 2016 Oct 6. Erratum in: Neuropsychopharmacology. 2017 Aug;42(9):1924.

5.

Clinical population pharmacokinetics and toxicodynamics of linezolid.

Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2014;58(4):2334-43. doi: 10.1128/AAC.01885-13. Epub 2014 Feb 10.

6.

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D.

Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006. Review.

PMID:
19026027
7.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

8.

Population pharmacokinetics of oseltamivir when coadministered with probenecid.

Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN.

J Clin Pharmacol. 2008 Aug;48(8):935-47. doi: 10.1177/0091270008320317. Epub 2008 Jun 4.

PMID:
18524996
9.

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Boak LM, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. Epub 2007 Jan 22.

10.

Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis.

Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1451-5. Epub 2006 Jun 13.

PMID:
16772405
11.

High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma.

Boak LM, Li J, Nation RL, Rayner CR.

Biomed Chromatogr. 2006 Aug;20(8):782-6.

PMID:
16292746
12.

Responses to neither exogenous nor endogenous endothelin-1 are altered in patients with hypercholesterolemia.

Boak LM, Dart AM, Duffy SJ, Chin-Dusting JP.

J Lipid Res. 2005 Dec;46(12):2667-72. Epub 2005 Sep 21.

13.

Hypercholesterolemia and endothelium dysfunction: role of dietary supplementation as vascular protective agents.

Boak L, Chin-Dusting JP.

Curr Vasc Pharmacol. 2004 Jan;2(1):45-52. Review.

PMID:
15320832
14.

The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism.

Chin-Dusting JP, Boak L, Husband A, Nestel PJ.

Atherosclerosis. 2004 Sep;176(1):45-8.

PMID:
15306173
15.

Pharmacy practice: workload measurement.

Boak LR.

Can J Hosp Pharm. 1988 Aug;41(4):205-10. No abstract available.

PMID:
10288852

Supplemental Content

Support Center